Nagpur-based ZIM Labs gets marketing authorization for Rizatriptan in Portugal, Europe

Migraine is often associated with symptoms such as nausea, vomiting, phonophobia (sensitivity to sound), and photophobia (sensitivity to light) and because of the severity of the symptoms it needs medication that can be given to patient without making these symptoms worse and that also produces a faster onset of action.

Rizatriptan Orally Dissolving Film is a product developed using Thinoral technology which yields instantly wettable, rapidly dissolving, and stable films. The fast dissolving feature provides potentially faster onset of action, and the flexible nature of film dosage form allows for convenience in handling and administration.

"As the presently available product in the market is a mouth dissolving tablet which is extremely fragile, Zim's product offering is likely to provide significant advantage to patients in terms of portability as well as faster action. Rizatriptan orally dissolving film by virtue of its convenience in administration ensures treatment adherence and will help to reduce economic burden," the company said.

The global market of Rizatriptan is about 200 million USD.

Commenting on the granting of the marketing authorisation, Dr. Anwar Daud, Managing Director of Zim Laboratories Limited said, "The approval of this novel orally dissolving film is further evidence of Zim Lab's determination to become the preferred partner for our clients who are seeking innovative new therapies to treat unmet needs for the patients and physicians."

Read also: Jubilant gets approval for anti-migraine drug from FDA